The publications were excited to report that EPCON had received funding of €500,000, allowing new CEO Caroline Van Cauwelaert the opportunity to turn her worthwhile ambitions into reality. EPCON plans to use the investment to develop its AI engine further, tackle diseases such as HIV, malaria and dengue, and lifestyle diseases such as diabetes. EPCON also plans to strengthen its team, both in Belgium and South Africa, and to offer its services in other regions.
top of page
bottom of page